Compare Alcon AG (ALC) vs Vale SA (VALE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Vale SA — how do they compare? Alcon AG trades at $66.77 (market cap $32.69B), while Vale SA trades at $14.14 (market cap $62.60B). The key difference: Vale SA is the larger of the two by market cap, and Vale SA pays the higher dividend (8.57%). Which is the better fit depends on your goals.
| ALC | VALE | |
|---|---|---|
Market Cap | $32.69B | $62.60B |
Sector | Health | Basic Materials |
52-Week High | $92.22 | $17.82 |
52-Week Low | $62.02 | $9.53 |
Enterprise Value | $36.28B | $79.52B |
Dividend Yield | 0.54% | 8.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
VALE trades at $14.69, down 2.0% over the past day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q3 2025 but missing in Q4 2025 and Q1 2026. Revenue for 2025 was $38.40 billion with a net income margin of 7.21%, while cash flow from operations remained strong at $8.80 billion. Recent news includes a board governance dispute and a $2.56 billion decarbonization investment plan announced on June 15, 2026 (Reuters).
The outlook is cautious with a consensus analyst price target of $18.30, implying potential upside, but risks include volatile iron ore prices, rising debt-to-asset ratios, and execution challenges. Earnings growth and cost management are key catalysts for stock performance amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
